Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-17T02:26:50.342Z Has data issue: false hasContentIssue false
  • English
  • Français

Biomarkers of depressive disorders: A multiplex analysis of blood serum

Published online by Cambridge University Press:  23 March 2020

A.S. Boiko ,
I.S. Losenkov ,
L.A. Levchuk ,
G.G. Simutkin ,
N.A. Bokhan ,
F.J. Bosker ,
B. Wilffert ,
A.J.M. Loonen  and
S.A. Ivanova
A.S. Boiko
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center, Laboratory of Molecular Genetics and Biochemistry, Tomsk, Russia
I.S. Losenkov
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center, Laboratory of Molecular Genetics and Biochemistry, Tomsk, Russia
L.A. Levchuk
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center, Laboratory of Molecular Genetics and Biochemistry, Tomsk, Russia
G.G. Simutkin
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center, Department of Clinical Psychiatry, Tomsk, Russia
N.A. Bokhan
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center, Department of Clinical Psychiatry, Tomsk, Russia
F.J. Bosker
Affiliation:
University of Groningen, University Centre for Psychiatry, Groningen, The Netherlands
B. Wilffert
Affiliation:
University of Groningen, Department of Pharmacy, Groningen, The Netherlands
A.J.M. Loonen
Affiliation:
University of Groningen, Department of Pharmacy, Groningen, The Netherlands
S.A. Ivanova
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center, Laboratory of Molecular Genetics and Biochemistry, Tomsk, Russia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Depressive disorders are a great burden for individual patients and society. Blood-based biomarkers are regarded as a feasible option for investigation of depressive disorders. Several potential biomarkers for depression were selected. We studied the following serum markers: cortisol, melatonin, brain-derived neurotrophic factor (BDNF), prolactin, insulin-like growth factor 1 (IGF-1), β-endorphin, orexin A. The patient sample consisted of 78 persons with depressive disorders. Patients were divided into two groups: 46 patients with a first depressive episode and 32 patients with recurrent depressive disorder. Control group consisted of 71 healthy individuals of corresponding age and sex. All markers were measured in serum using MILLIPLEX® MAP panels (Merck, Darmstadt, Germany) by analyzer MAGPIX (Luminex, USA). Statistical analyses were performed using SPSS software. Results were expressed as median and quartile intervals [Q1–Q3]. There was a significant increase of serum concentrations of cortisol (663.69 [467.5–959.49] nmol/L, Р < 0.001) and melatonin (66.31 [33.6–132.59] pg/mL, P = 0.029) in patients compared with the control group (526.1 [367,24–654,7] nmol/L and 45.11 [27.47–73.47] pg/mL). In addition, correlations were found between potential biomarkers, clinical indicators and treatment response measured by applying the Hamilton Depression rating scale and the Clinical Global Impression rating scales. A significant correlation was found between the concentration of prolactin and high response to pharmacotherapy (r = –0.267, P = 0.029). Identifying biomarkers that can be used as diagnostics or predictors of treatment response in people with depressive disorders will be an important step towards being able to provide personalized treatment.

Disclosure of interest

The work is supported by the project of Russian Foundation of Basic Research No 14-04-01157a.

Type
e-Poster viewing: Cultural psychiatry
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S524
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.